Guizhounli Pharmaceutical Co (SHSE:603439) ROCE % : 13.83% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Guizhounli Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 13.83%.

Guizhounli Pharmaceutical Co ROCE % Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co ROCE % Chart

Guizhounli Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

26.11

13.51

18.14

19.70

20.19

Guizhounli Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															19.66	15.03	18.43	34.04	13.83

Guizhounli Pharmaceutical Co ROCE % Calculation

Guizhounli Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	338.155	/	( ( (1816.619 - 548.683)	+	(2920.451 - 839.01) )	/ 2 )
	=	338.155	/	( (1267.936	+	2081.441)	/ 2 )
	=	338.155	/	1674.6885
	=	20.19 %

Guizhounli Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	293.404	/	( ( (2920.451 - 839.01)	+	(2946.6 - 783.67) )	/ 2 )
	=	293.404	/	( ( 2081.441	+	2162.93 )	/ 2 )
	=	293.404	/	2122.1855
	=	13.83 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Guizhounli Pharmaceutical Co (SHSE:603439) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Guizhounli Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Guizhounli Pharmaceutical Co (SHSE:603439) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000

Website

http://www.gz-sanli.com

Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.

Executives

Zhang Hong Yu	Directors, senior managers
Wang Yi	senior management
Zhang Qian Fan	Directors, senior managers
Sheng Yong Jian	Director

Guizhounli Pharmaceutical Co (SHSE:603439) Headlines

No Headlines